Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPM for Non-myoinvasive Bladder Cancer
NCT05519241Phase 1Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2022
- Primary completion
- Aug 2027
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PLZ4-coated paclitaxel-loaded micelles in non-muscle-invasive bladder cancer (NMIBC), sponsored by VA Office of Research & Development. Primary endpoint: Adverse Events. Started Oct 2022; status: recruiting.
02
Drugs
PLZ4-coated paclitaxel-loaded micelles
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05519241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519241.